Günther Adolf, formerly vice president of pharmacology at Boehringer Ingelheim GmbH, is one of four executives to join a new scientific advisory board set up by MorphoSys AG to advise it on research and development strategy.
The other members of the board are Bruce Cheson, professor of medicine at the Georgetown University Hospital in Washington DC; Sergio Quezada, group leader of immune regulation and tumour immunotherapy at the University College London Cancer Institute and Raymond Sweet, former senior director and fellow of biologics research at Janssen (Johnson & Johnson Inc).
The appointments were announced on 12 September 2016.
Copyright 2016 Evernow Publishing Ltd